Compare
Royalty Pharma plc vs Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc. vs Jazz Pharmaceuticals plc
| Latest fiscal year | Royalty Pharma plc RPRX | Sarepta Therapeutics, Inc. SRPT | Amneal Pharmaceuticals, Inc. AMRX | Jazz Pharmaceuticals plc JAZZ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.38B | $2.20B | $3.02B | $4.27B |
| Revenue growth (YoY) | +5.1% | +15.6% | +8.0% | +4.9% |
| Gross margin | n/a | n/a | 36.9% | n/a |
| Operating margin | 65.6% | -31.8% | 13.1% | -10.1% |
| Net margin | 32.4% | -32.5% | 2.4% | -8.3% |
| Net income | $770.95M | -$713.41M | $72.06M | -$356.15M |
| EPS (Diluted) | $1.78 | -$7.13 | $0.22 | -$5.84 |
| Operating cash flow | $2.49B | -$205.48M | $339.99M | $1.36B |
| Free cash flow | n/a | -$307.45M | $269.93M | $1.30B |
| Cash & equivalents | $618.70M | $801.28M | $282.03M | $1.39B |
| Total assets | $19.62B | $3.35B | $3.68B | $11.66B |
| Total liabilities | $9.91B | $2.21B | n/a | n/a |
| Shareholders' equity | $9.71B | $1.14B | -$70.79M | $4.32B |
| Return on year-end equity | 7.9% | -62.5% | n/a | -8.2% |
| Shares outstanding | n/a | 104.96M | n/a | 61.44M |
Revenue, most recent five fiscal years
| Fiscal year | Royalty Pharma plc | Sarepta Therapeutics, Inc. | Amneal Pharmaceuticals, Inc. | Jazz Pharmaceuticals plc |
|---|---|---|---|---|
| Latest | $2.38B Ended 2025-12-31 | $2.20B Ended 2025-12-31 | $3.02B Ended 2025-12-31 | $4.27B Ended 2025-12-31 |
| 1 year earlier | $2.26B Ended 2024-12-31 | $1.90B Ended 2024-12-31 | $2.79B Ended 2024-12-31 | $4.07B Ended 2024-12-31 |
| 2 years earlier | $2.35B Ended 2023-12-31 | $1.24B Ended 2023-12-31 | $2.39B Ended 2023-12-31 | $3.83B Ended 2023-12-31 |
| 3 years earlier | $2.24B Ended 2022-12-31 | $933.01M Ended 2022-12-31 | $2.21B Ended 2022-12-31 | $3.66B Ended 2022-12-31 |
| 4 years earlier | $2.29B Ended 2021-12-31 | $701.89M Ended 2021-12-31 | $2.09B Ended 2021-12-31 | $3.09B Ended 2021-12-31 |